Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will receive ...
The FDA has started its review of a subcutaneous injection formulation of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to receive maintenance doses at home, rather than in an ...
Objectives To investigate the efficacy and safety of subcutaneous clonidine for refractory symptoms in the palliative setting. Methods A retrospective chart review of the use of subcutaneous clonidine ...
Objectives To investigate the efficacy and safety of subcutaneously (SC) administered tranexamic acid. Methods A retrospective chart review of the use of SC tranexamic acid in a single palliative care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results